DISEASE
TYPE · TARGET
MECHANISM
CLUE
Autoimmune hemolytic anemia
II · RBC antigens
Warm IgG → splenic removal (spherocytes) · cold IgM → complement
Direct Coombs ⁺
II · GPIIb/IIIa
IgG-coated platelets cleared by splenic macrophages
Isolated low platelets, normal marrow
Hemolytic disease of the newborn
II · fetal Rh(D) RBCs
Maternal anti-D IgG crosses placenta
Prevented by anti-D immune globulin (RhoGAM)
Goodpasture (anti-GBM) disease
II · type IV collagen α3
Complement + neutrophils in glomeruli and alveoli
Hemoptysis + RPGN · linear IgG on IF
II · cardiac myosin (mimicry with M protein)
Cross-reacting antibodies after GAS pharyngitis
Aschoff bodies, mitral damage
Pemphigus vulgaris · bullous pemphigoid
II · desmoglein 1/3 · hemidesmosome (BP180/230)
Acantholysis (intraepidermal) · subepidermal split
Flaccid bullae, ⁺ Nikolsky, mucosa · tense bullae, elderly
Graves disease · myasthenia gravis
II · TSH receptor · ACh receptor
Stimulating · blocking antibodies (no cell damage)
Transient neonatal disease from maternal IgG
II · parietal cells / intrinsic factor
Loss of IF → B12 deficiency
Atrophic gastritis of body/fundus
Systemic lupus erythematosus
III · nuclear antigens (DNA, histones)
Immune complexes in skin, joints, kidney, serosa
↓ C3/C4 in flares · also type II cytopenias
III · streptococcal antigens
Subepithelial humps, complement consumption
Cola urine 2–3 weeks after infection · ↓ C3
Polyarteritis nodosa · cryoglobulinemia
III · HBV antigens · HCV-related IgM-IgG
Vessel-wall complexes
PAN spares lungs · palpable purpura, low C4
III · foreign proteins (antivenom, rituximab, infliximab) or drugs (penicillin, cefaclor, TMP-SMX)
Antibodies form after ~1–2 weeks; complexes deposit
Fever, urticarial rash, arthralgia, lymphadenopathy, proteinuria, ↓ C3
III · local antigen (tetanus/diphtheria booster) with high preexisting IgG
Complexes in dermal vessels → local vasculitis, necrosis
Hours after injection